Intravitreal injection of ranibizumab for foveal-macular pattern dystrophy: case report

ALEXANDRE AUGUSTO CABRAL DE MELLO VENTURA1, LORNA WINIFRED GRANT2, HAJR DADGOSTAR2, HILEL LEWIS2

ABSTRACT
In the recent years, anti-angiogenic medications have successfully treated other diseases associated with choroidal neovascularization. The anti-angiogenic therapy alone or combined with LASER and/or steroids has been effective in controlling ocular neovascularization, not only restricted to the treatment of typical membranes due to macular degeneration in the wet form. The discovery and subsequent use of these drugs has revolutionized medicine and ophthalmology. This report illustrates an example of successful treatment in a challenging pathology where it was found important visual and anatomical response after the use of ranibizumab.

Keywords: Fovea centralis; Lutein; Retinal pigments; Tomography, optical coherence; Macula lutea; Macular degeneration; Fluorescein angiography; Choroidal neovascularization; Antibodies, monoclonal/therapeutic use; Intravitreal injections

INTRODUCTION
Foveal-macular pattern dystrophies (FMPD) are a group of autosomal dominant disorders that involve degeneration of the retinal pigment epithelium and retina (1). In the presence of choroidal neovascularization (CNV) these macular patterns are often confused with age-related macular degeneration (AMD)(2). In 2007 a case was reported in using intravitreal bevacizumab which yielded only visual acuity stabilization.(3)(4). We report the first case of FMPD in which visual acuity and morphologic disease improved after treatment with intravitreal ranibizumab.

CASE REPORT
A 59-year-old Caucasian woman with fundus changes in her right eye was referred to our clinic for evaluation of AMD. Ocular history included macular photocoagulation for presumed AMD in her left eye. Family history was positive for adult-onset foveal-macular pattern dystrophy inherited in an autosomal dominant pattern (Figure 1A). Best-corrected visual acuity (BCVA) was 20/30 in her right eye and 20/400 in the left. Fundoscopy revealed foveal-macular pattern dystrophy in the right eye and a fibrovascular membrane secondary to macular photocoagulation in the left eye. Fluorescein angiography (FA) and optical coherence tomography (OCT) of the right eye showed subretinal hemorrhage and early hyperfluorescence with progressive leakage likely representing para-foveal CNV (Figure 2). This eye was then treated with intravitreal injections of bevacizumab for three consecutive months. When her visual acuity continued to decline to 20/50, laser photocoagulation was performed. Two months later her vision stabilized to 20/40. At that time her first intravitreal injection of ranibizumab was administered.

One month after ranibizumab injection BCVA in the right eye improved to 20/30. Exams showed no subsensory fluid and an area of leakage representing either atrophy of the choriocapillaris or persistent neovascularization. Eight months after injection BCVA was 20/20 in the right eye and subsensory fluid remained absent. Over the next six months BCVA declined again to 20/40. Two more injections of ranibizumab were administered and vision returned to 20/25 (Figure 1B).

DISCUSSION
Interestingly this patient’s visual acuity declined after treatment with bevacizumab, but improved substantially after ranibizumab injection. Of note, laser photocoagulation was performed two months prior to the first ranibizumab injection. Thus, possibly laser and ranibizumab work additively or synergistically to improve vision. It is unlikely that the improvement from months 6-16 was due solely to the laser since vision also improved after the second dose of...
INTRAVITREAL INJECTION OF RANIBIZUMAB FOR FOVEAL-MACULAR PATTERN DYSTROPHY: CASE REPORT

Figure 1. A) Autosomal dominant inheritance foveal-macular pattern dystrophy. The arrow indicates the patient described in this case. Relatives affected by this disease are shown with solid fill; B) Visual improvement after ranibizumab injection. Best-corrected visual acuity (BCVA) testing shows a 3 line increase 1 month after the first injection of ranibizumab. After the second injection of ranibizumab VA improves 2 lines.

Figure 2. Morphologic improvement post ranibizumab injection. A-C) Red-free retinography (RFR) and fluorescein angiography (FA) before injection show subretinal hemorrhage and foveal-macular lesions with progressive hyperfluorescence. D) Optical coherence tomography (OCT) prior to injection reveals subretinal fluid (SRF). E-G) RFR and FA show disappearance of lesions and leakage, and a disciform scar 1 month after injection. H) OCT 1 month after injection with absence of SRF.
ranibizumab given alone (Figure 1B). In conclusion, in this patient with FMPD, intravitreal ranibizumab had a therapeutic effect indicated by improved VA and anatomic disease either independent of, or augmented by, prior laser photocoagulation. Further case series are needed to confirm this effect.

REFERENCES